ARCT is not a standalone therapy by itself; rather, it is the official Nasdaq stock ticker symbol for Arcturus Therapeutics Holdings Inc., a clinical-stage biotechnology enterprise. However, the company itself develops advanced genetic medicines, proprietary messenger RNA platforms, and specialized lipid nanoparticle delivery systems designed to create novel vaccines and targeted genetic therapies for rare respiratory and liver diseases.